A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Bb-21217 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors bluebird bio
- 02 Nov 2023 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 04 Nov 2021 According to a 2seventy bio media release, data from the study will be presented at he 63rd American Society of Hematology (ASH) Annual Meeting and Exposition 2021, virtually.